Results 81 to 90 of about 21,745 (180)

Current Management of In-Stent Restenosis

Journal of Clinical Medicine
In-stent restenosis (ISR) remains the primary cause of target lesion failure following percutaneous coronary intervention (PCI), resulting in 10-year incidences of target lesion revascularization at a rate of approximately 20%. The treatment of ISR is challenging due to its inherent propensity for recurrence and varying susceptibility to available ...
Giacoppo, Daniele, Mazzone, Placido Maria, Capodanno, Davide   +2 more
openaire   +2 more sources

The association between epicardial fat thickness in echocardiography and coronary restenosis in drug eluting stents

ARYA Atherosclerosis, 2011
BACKGROUND: The association between epicardial fat and coronary in-stent restenosis hasnot been evaluated. The objective of the present study was to evaluate the relationship ofechocardiographic epicardial fat thickness (EFT) with restenosis in drug ...
Fariborz Nikaeen, Masoud Pourmoghadas, Hasan Shemirani, Seid Ahmad Mirdamadi, Mojtaba Akbari   +4 more
doaj  

The Role Of Inflammation In Stent Restenosis More Than 1 Year Afetr Drug Eluting Stent Implantation

Iranian South Medical Journal, 2011
Background: In stent restenosis (ISR) following endovascular interventions is the main limitation of their long-term success. Despite advances have been made during recent years to decrease restenosis, it remains a challenging clinical problem.The aim of
Hasan Shemirani, Fatemeh Nekooie, Masood Pourmoghaddas   +2 more
doaj  

Recurrent In-Stent Restenosis Treated With a Novel Technique: The Double-DCB Technique. [PDF]

JACC Case Rep
Ang AS, Khaing T, Khialani B, Loh KKJ, Ho HH.   +4 more
europepmc   +1 more source

CTRP12: A Novel Biomarker in Predicting In-Stent Restenosis Occurrence. [PDF]

Clin Cardiol
Nie Y, Song W.
europepmc   +1 more source

Methodological Considerations in Evaluating CTRP12 as a Biomarker for In-Stent Restenosis. [PDF]

Clin Cardiol
Khattak S, Rayyan SM, Khan SH.
europepmc   +1 more source

Glucocorticoid Therapy for Recurrent In-Stent Restenosis: A Prospective Explorative Case Series. [PDF]

JACC Case Rep
Yu M, Yan HY, Wei ZY, Jiang Y, Song ZF, You HZ, Yang WX, Qian HY.   +7 more
europepmc   +1 more source

In-Stent Restenosis [PDF]

Cardiovascular Therapeutics, 2010
Michael S. Kim, Larry S. Dean
openaire   +1 more source

Peculiarities of in-Stent Thrombosis and Restenosis in Coronary Arteries Post-COVID-19: A Systematic Review of Clinical Cases and Case Series

Open Access Emergency Medicine
Lyudmila Pivina,1 Gulnara Batenova,1 Nazarbek Omarov,1 Diana Ygiyeva,1 Assylzhan Messova,1 Galiya Alibayeva,2 Ulzhan Jamedinova,1 Ruslan Kurumbayev,1 Maksim Pivin3 1Department of Emergency Medicine, Semey Medical University, Semey, Abay Region ...
Pivina L, Batenova G, Omarov N, Ygiyeva D, Messova A, Alibayeva G, Jamedinova U, Kurumbayev R, Pivin M   +8 more
doaj  

Drug-Coated Balloons Beyond In-Stent Restenosis. [PDF]

Rev Cardiovasc Med
Gupta R, Bohra C, Vemuri KS, Arora G, Gulati A, Ranadive I, Sharma SK, Hooda A.   +7 more
europepmc   +1 more source